

Royal College of Anaesthetists

WINTER SYMPOSIUM




3-4 December 2020

COVID-19 Chair: Dr Jamie Strachan

What Intensive Care Medicine has learned
Dr Alison Pittard OBE

PPE
Professor William Harrop-Griffiths

Risks to healthcare workers
Professor Tim Cook



Is it safe?


Prof Tim Cook
Bath

Twitter @doctimcook
Email timcook007@gmail.com

Is the population safe?

Are hospitals safe?

Are anaesthetist and intensivists safe?





Is the population safe?


Context – 25 Sept


About 90% of population still at risk of COVID-19 (London 80%)
 Desire to re-establish and maintain planned surgery (Simon Stephens)
 Surgical priorities set by RCS
 Reduced NHS hospital capacity (expanded ICUs, COVID-19 care, socially distanced beds)
 Stress on system likely to rise over winter
 Current evidence of rising rates of COVID-19 throughout UK (ONS)


COVIDsurg
 NICE 179 July 2020
 PHE changes Sept 2020














#TheAnaesthesiaBlog
Peri-operative medicine, critical care and pain

About Blog Journal Open Access Special collections Patients

The UK COVID-19 epidemic: time to plan and time to act

<https://theanaesthesia.blog>
@Anaes_Journal

March 9

NEW! NEW! 2020 Anaesthesia Society (BOA) MEDICAL AND EDUCATIONAL PERSONAL PROTECTIVE EQUIPMENT COURSE THE COVID-19 PANDEMIC


RECENT POSTS

- [Twitter](#)
- [Facebook](#)
- [LinkedIn](#)
- [YouTube](#)


SOCIAL

TWEETS


<https://theanaesthesia.blog/2020/03/09/the-uk-covid-19-epidemic-time-to-plan-and-time-to-act/>



Risk



Risk of (harm from) COVID



Patients at risk of harm from COVID

3 major risk factors

Age: mortality from COVID rises 12% each year of age

Age: mortality risk doubles (200%) every 5-6 years

Age: mortality risk rises 10-fold (1000%) each generation (20 yrs)



<https://medium.com/wintoncentre/what-have-been-the-fatal-risks-of-covid-particularly-to-children-and-younger-adults-e5cbf7060c49>

Patients at risk of harm from COVID

3 major risk factors

Age: mortality from COVID rises 12% each year of age
 Age: mortality risk doubles (200%) every 5-6 years
 Age: mortality risk rises 10-fold (1000%) each generation (20 yrs)

Age 65-74 vs 15-44

- half as likely to get COVID-19
- 100x more likely to die from it

REACT-2

<https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2.full.pdf>

Patients at risk of harm from COVID

3 major risk factors

Age
 Age
 Age

3 lesser risk factors

Sex – male risk up 70%
 Ethnicity – non-white risk up 50-100%
 Comorbidity – risk up 10-200%

ANALYSIS



¹ Winton Centre for Risk and Evidence
 Communications, Statistical
 Laboratory Centre for Mathematical
 Sciences, Cambridge, UK.

<https://doi.org/10.1136/bmj.m3259>
 Cite this as: *BMJ* 2020;370:m3259
 Published: 09 September 2020

Use of “normal” risk to improve understanding of dangers of covid-19

Accumulating data on deaths from covid-19 show an association with age that closely matches the “normal” risk we all face. Explaining risk in this way could help people understand and manage their response, says **David Spiegelhalter**


David Spiegelhalter *chair*¹


As covid-19 turns from a societal threat into a matter of risk management, it is vital that the associated risks are understood and clearly communicated.¹ But these risks vary hugely between people, and so finding appropriate analogues is a challenge. Although covid-19 is a complex multisystem disease that can cause prolonged illness, here I focus solely on the risks of dying from covid-19 and explore the use of “normal” risk—the risk of death from all causes each year—as an aid to transparent communication.


from and with the virus, while underestimating the true number of deaths linked to covid-19 because of underdiagnosis in people who did not display classic symptoms, were not tested, and so did not have covid-19 mentioned on the death certificate.


In the 16 weeks (112 days) between 7 March and 26 June 2020, 218 354 deaths were registered in England and Wales, compared with an average of 159 595 for this period over the past five years. This is an absolute excess of 58 759 deaths, corresponding to a relative


<https://www.bmj.com/content/370/bmj.m3259>




















Risk factors

Anaesthesia 2020 doi:10.1111/anae.15220

Review Article



Risk to health from COVID-19 for anaesthetists and intensivists – a narrative review

T.M. Cook


Consultant, Royal United Hospital, Bath, UK and Honorary Professor of Anaesthesia, University of Bristol, UK


Summary

Healthcare workers are at an increased risk of infection, harm and death from COVID-19. Close and prolonged exposure to individuals infectious with SARS-CoV-2 leads to infection. A person's individual characteristics (age, sex, ethnicity and comorbidities) then influence the subsequent risk of COVID-19 leading to hospitalisation, critical care admission or death. While relative risk is often reported as a measure of individual danger, absolute risk is more important and dynamic, particularly in the healthcare setting. Individual risk interacts with exposure and environmental risk-factors, and the extent of mitigation to determine overall risk. Hospitals are a unique environment in which there is a significantly increased risk of infection for all healthcare workers. Anaesthetists and intensivists particularly are at high risk of exposure to SARS-CoV-2 infected patients due to their working



Long COVID






Is the population safe?

Are hospitals safe?

UK COVID hospital admissions



Sir Simon Stephens 3rd phase plan

31 July



Skipiton House
80 London Road
London SE1 8LH
england.spsoc@nhs.net

From the Chief Executive Sir Simon Stevens
& Chief Operating Officer Amanda Pritchard

To:
Chief executives of all NHS trusts and foundation trusts
CCG Accountable Officers
GP practices and Primary Care Networks
Providers of community health services
NHS 111 providers

Cc: to:
NHS Regional Directors

Restore full operation of all cancer services
Recover the maximum elective activity possible between now and winter
- 80% September
- 90% October

Open: 3/08/2020

IMPORTANT – FOR ACTION – THIRD PHASE OF NHS RESPONSE TO COVID-19

Tameside hospital Covid deaths are 'canary in the mine'

Rise in mortalities indicate consequences of lack of test and trace,
says public health chief
- Coronavirus - latest updates
- See all our coronavirus coverage



▲ People queue at a temporary Covid-19 test site in the grounds of the Victoria Centre in Bury, Greater Manchester

<https://www.theguardian.com/politics/2020/sep/16/tameside-hospital-covid-deaths-are-canary-in-the-mine>



Plans to ration Covid testing in England will prioritise healthcare and teachers

Government promises to publish tiered system, while Labour says
country is being taken back to April
- Coronavirus - latest updates
- See all our coronavirus coverage




▲ People queueing for tests in Bury, which has seen a surge in Covid cases. Boris Johnson said the mass use of testing was the 'only way off' (Photograph: BBC/Neil Hall)

Rationing plans for coronavirus tests in England will prioritise NHS patients, staff, care homes and key workers - especially teachers - as the government grapples with a surge in demand
<https://www.theguardian.com/world/2020/sep/16/teachers-to-top-englands-covid-test-list-as-rationing-returns>

Why is coming into hospital dangerous?

- 1 Attending while brewing COVID
- 2 Getting COVID in hospital
 - from other patients
 - from staff
- 3 Post operative immunosuppression and debilitation increasing risk from subsequent COVID-19

Sethuraman et al JAMA April 2020



medRxiv
THE PREPRINT SERVER FOR HEALTH SCIENCES



BMJ Yale

HOME | ABOUT
| ALERTS / RSS

Search

SARS-CoV-2, SARS-CoV-I and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis

[Comments \(2\)](#)

Muge Cevik, Matthew Tate, Oliver Lloyd, Alberto Enrico Maraolo, Jenna Schafers, Antonia Ho

doi: <https://doi.org/10.1101/2020.07.25.20162107>

<https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v2>

COVID-19 viral dynamics

Incubation	around 5d (up to 14)
Viral secretion (infectious)	up to 9d
Maximum infectivity	probably day 0-5 of symptoms
Maximum transmission	day 0-5
Asymptomatic infection	certainly

	Mean duration	Maximum	Maximum
Upper Respiratory tract	17	83	9
Lower Respiratory tract	14.6	59	9
Stool	17.2	35	
Serum	16.6	60	

<https://www.medrxiv.org/content/10.1101/2020.07.25.20162107v2>

NICE 27 July

NICE National Institute for Health and Care Excellence

Search NICE... Sign In

NICE Pathways NICE guidance Standards and indicators Evidence search BNF BNFC CKS Journals and databases

Coronavirus (COVID-19)

For information on how NICE is supporting the NHS and social care, view our new [rapid guidelines and evidence submission](#). Learn about the [government coronavirus](#) on GOV.UK.

Close

Home > NICE Guidance > Conditions and diseases > Infections > COVID-19

COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services

NICE guideline [NG179] Published date: 27 July 2020

<https://www.nice.org.uk/guidance/ng179>



NICE

All planned procedures needing anaesthesia (general, regional and local) or sedation




- 3.7 Advise test if they can have a SARS-CoV-2
- 3.8 Advise **'Low risk patients'** = Self-isolate for up to 3 days only
- follow comprehensive social-distancing and hand-hygiene measures for 14 days before admission (see [government advice on social distancing](#))
 - have a test for SARS-CoV-2 from 3 days before admission, and ensure the results are available beforehand
 - self-isolate from the day of the test until admission.

NICE guideline [NG179] Published date: 27 July 2020

• <https://www.nice.org.uk/guidance/ng179>



9 September

COVID-19: Guidance for the remobilisation of services within health and care settings


Infection prevention and control recommendations

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/ppe-guidance-by-healthcare-context>

9 September





COVID-19: Guidance for the remobilisation of services within health and care settings

Infection prevention and control recommendations

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/ppe-guidance-by-healthcare-context>

Patients/Individuals treatment, care and support to be managed in 3 COVID-19 pathways:

- **High risk:** There is no change in recommendations for IPC or for the use of PPE by staff when managing patients/individuals who have, or are likely to have, COVID-19
- **Medium risk:** This includes patients/individuals who have no symptoms of COVID-19 but do not have a COVID-19 SARS- CoV-2 PCR test result.
- **Low risk:** Patients/individuals with no symptoms and a negative COVID-19 SARS- CoV-2 PCR test who have self-isolated prior to admission for example following NICE guidance

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/ppe-guidance-by-healthcare-context>

5. Standard Infection Prevention Control Precautions (SICPs): all pathways or settings

SICPs are the basic IPC measures necessary to reduce the risk of transmitting infectious agents from both recognised and unrecognised sources of infection and are required across ALL COVID-19 pathways.

remobilisation of services within health and care settings

Infection prevention and control recommendations

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control@ppe-guidance-by-healthcare-context>

7.3.1 Operating theatres and procedure rooms

Within the low risk COVID-19 pathway, standard theatre cleaning and time for air changes provides appropriate levels of IPC and there is no requirement for additional cleaning or theatre down time unless the patient has another infectious agent that requires additional IPC measures.

7.4 Aerosol Generating Procedures (AGPs): procedures that create a higher risk of respiratory infection transmission

Airborne precautions are NOT required for AGPs on patients/individuals in the low risk COVID-19 pathway, providing the patient has no other infectious agent transmitted via the droplet or airborne route.

There is no additional requirement for ventilation or downtime in this pathway, providing safe systems of work, including engineering controls are in place.

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control@ppe-guidance-by-healthcare-context>

5. Standard Infection Prevention Control Precautions (SICPs): all pathways or settings

SICPs are the basic IPC measures necessary to reduce the risk of transmitting infectious agents from both recognised and unrecognised sources of infection and are required across ALL COVID-19 pathways.

8. Transmission Based Precautions (TBPs)

Transmission Based Precautions (TBPs) are additional measures (to SICPs) required when caring for patients/ individuals with a known or suspected infection such as COVID-19.

<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control@ppe-guidance-by-healthcare-context>

Public Health England NHS

COVID-19: Guidance for the remobilisation of services within health and care settings
Infection prevention and control recommendations


High and medium risk paths: transmission based precautions


- Airborne PPE for AGPs
- Fallow time after anaesthetic interventions
- Supplemented cleaning


Low risk pathways: standard infection control procedures


- none of the above


<https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/ppe-guidance-by-healthcare-context>














COVIDsurg [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31182-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31182-X/fulltext)

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

COVIDsurg Collaborative*

Summary
Background The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection.

Methods This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation.

Findings This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74.0%) had emergency surgery and 280 (24.8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in

Published Online: May 29, 2020
[https://doi.org/10.1016/S0140-6736\(20\)31182-X](https://doi.org/10.1016/S0140-6736(20)31182-X)
See Online/Comment: [https://doi.org/10.1016/S0140-6736\(20\)31256-3](https://doi.org/10.1016/S0140-6736(20)31256-3)
*Collaborating authors are listed in the appendix (pp 1-7)
Correspondence to: Mr Anand Bhargava, National Institute for Health Research Global Health Research Unit on Global Surgery, Heriote

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31182-X/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31182-X/fulltext)

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

COVIDsurg Collaborative*

Summary
Background The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection.

Methods This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation.

Findings This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74.0%) had emergency surgery and 280 (24.8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in

24% 30-d mortality
51% severe pulmonary complications

Mortality risks	odds ratio
ASA ≥3-5	2.35 [1.57-3.53], p<0.0001
age ≥70 years	2.30 [1.65-3.22], p<0.0001
male sex	1.75 [1.28-2.40], p<0.0001
Emergency	1.67 [1.06-2.63], p=0.026
Cancer surgery	1.55 [1.01-2.39], p=0.046
Major vs minor	1.52 [1.01-2.31], p=0.047

24 countries included all patients undergoing surgery between Jan 1 and March 31, 2020. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation.

Mortality Unaffected by

Type of anaesthesia	Percentage
LA	31%
RA	22%
GA	25%

P=0.488

Published Online: May 29, 2020
[https://doi.org/10.1016/S0140-6736\(20\)31182-X](https://doi.org/10.1016/S0140-6736(20)31182-X)
See Online/Comment: [https://doi.org/10.1016/S0140-6736\(20\)31256-3](https://doi.org/10.1016/S0140-6736(20)31256-3)
*Collaborating authors are listed in the appendix (pp 1-7)
Correspondence to: Mr Anand Bhargava, National Institute for Health Research Global Health Research Unit on Global Surgery, Heriote

Patients for elective surgery 3 groups

- | | |
|-----------------------------------|---|
| 1. Low risk young patients | Carry on |
| 2. Higher risk and older patients | Shared decision making & inform of increased risk from hospital |
| 3. Patients who have had COVID-19 | Defer or MDT (incl anaesthesia); complex and unknown |

Available online at www.sciencedirect.com

Journal of Hospital Infection

Journal homepage: www.elsevier.com/locate/jhin

Nosocomial COVID-19 infection: examining the risk of mortality. The COPE-Nosocomial Study (COVID in Older PEople)

B. Carter^{a,1}, J.T. Collins^{b,1}, F. Barlow-Pay^c, F. Rickard^d, E. Bruce^e, A. Verduri^f, T.J. Quinn^g, E. Mitchell^h, A. Priceⁱ, A. Vilches-Moraga^j, M.J. Stechman^k, R. Short^m, A. Einarssonⁿ, P. Braude^h, S. Moug^o, P.K. Myint^p, J. Hewitt^{q,r,s}, L. Pearce^{s,2}, K. McCarthy^{t,2}, on behalf of the COPE Study Collaborators^l

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372282/pdf/main.pdf>

COPE-nosocomial

10 UK and 1 Italian hospitals

1564 COVID-19 patients

- | | | |
|-----------------------------|-------|----------------------|
| - 196 >15d after admission | 12.5% | (hospital acquired) |
| - 169 2-14d after admission | 10.8% | (uncertain)* |
| - 1199 0-1d after admission | 76.7% | (community acquired) |

*Uncertain were included in community-acquired

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372282/pdf/main.pdf>

COPE-nosocomial

Time to infection


Community acquired median 1d (IQR 0-1d)
 Hospital acquired median 32.5d (IQR 23-54)

LOS

Community acquired median 16d
 Hospital acquired median 33d

Mortality

Community acquired 27.2%
 Hospital acquired 27%



<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372282/pdf/main.pdf>

NEWS

Home | Coronavirus | US Election | UK | World | Business | Politics | Tech | Science | Health | Family

Health

Coronavirus: One in eight hospital cases were 'caught on-site'

By Nick Triggle
Health correspondent

4 hours ago

Coronavirus pandemic

Thousands of patients are likely to have been infected with coronavirus in UK hospitals, a study suggests.

The Group's findings suggest that up to 10% of hospital admissions are likely to be infected.

25 October

"they also had better outcomes than those admitted with the virus, probably because of faster diagnosis and, therefore, treatment."

"those caveats do suggest the risk of catching the virus in hospital remains still small."

ONS – PCR surveillance

Staying at home 1
 Working outside home 2.49 (1.4-4.5)

Non-patient facing work 1
 Patient facing work 4.06 (2.4-6.8)

Contact with hospital – personally 2.20 (1.1-4.2)
 Contact with hospital – household member 1.99 (0.9-4.1)

61% of +ves asymptomatic



<https://www.medrxiv.org/content/10.1101/2020.07.06.20147348v1>



Is the population safe?

Are hospitals safe?

Are anaesthetist and intensivists safe?

Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission


Lucy Rivett^{1,2†}, Sushmita Sridhar^{3,4,5†}, Dominic Sparkes^{1,2†}, Matthew Routledge^{1,2†}, Nick K Jones^{1,2,4,5†}, Sally Forrest^{4,5}, Jamie Young⁶, Joana Pereira-Dias^{4,5}, William L Hamilton^{1,2}, Mark Ferris⁷, M Estee Torok^{5,8}, Luke Meredith^{1,2,3,4,5,9}, Martin D Carr^{1,2,3,4,5,9}, Richard J Sam^{1,2,3,4,5,9}, Kenneth GC S^{1,2,3,4,5,9}, Ian G Goodfellow^{1,2,3,4,5,9}, Gordon Dougan^{1,5}, Nicholas J Matheson^{1,4,5,14}, Giles Wright⁷, Michael P Weekes^{1,4,5,14}

Cambridge 1032 HCWs April

[†]Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ²Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom; ³Wellcome Sanger Institute, Hinxton, United Kingdom; ⁴Department of Medicine, University of Cambridge, Cambridge, United Kingdom; ⁵Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom; ⁶Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ⁷Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ⁸Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ⁹Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ¹⁰Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ¹¹Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ¹²Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ¹³Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; ¹⁴Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom

<https://elifesciences.org/articles/58728>

Identification of clusters of cases



<https://elifesciences.org/articles/58728>

Identification of clusters of cases

Detection

- By screening mostly!
- Most asymptomatic




Figure 4. All SARS-CoV-2 positive HCW identified in Wards F and Q, stratified by their mechanism of identification. Individuals testing positive for SARS-CoV-2 in the 'HCW asymptomatic screening group' were identified by the asymptomatic screening programme. Individuals testing positive in the 'HCW symptomatic/symptomatic household contact group' were identified by self-presentation after developing symptoms. Individuals testing positive in the 'Reactive screening group' were identified by an 'intended screening programme' after initial positive clusters had been recognised. The prime version of this article includes the following figure supplement(s) for figure 4:

<https://elifesciences.org/articles/58728>

REACT-2 Imperial: 11.7% vs 6%

Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in

England: REACT2 study in 100,000 adults

National Real-time Assessment of Community Transmission-2 (REACT-2) prevalence study using a self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020.

Care home workers

HR 3.1

Patient-facing

HR 2

<https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2.full.pdf>

Oxford staff serology: 11% vs 6.8%

medRxiv THE PREPRINT SERVER FOR HEALTH SCIENCES

CSH BMJ Yale

Search

Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study [Comments \(1\)](#)

David W Eyre, Sheila F Lumley, Denise O'Donnell, Mark Campbell, Elizabeth Sims, Elaine Lawson, Fiona Warren, Tim J James, Stuart Cox, Alison Howarth, George Doherty, Stephanie B Hatch, James Kavanagh, Kevin K Chiu, Philip W Fowler, Jeremy Swann, Denis Volk, Dan Yang, Turner, Nicole E Soosier, Philipp C Matthews, Maria Dudasova, Timothy Davies, Robert H Shaw, Louis Peto, Louise O Downes, Alexander Vogt, Ali Amiri, Bernadette C Young, Philip Drennan, Alexander J Mentzer, Donal Skelly, Fredrik Karpe, Matthew J Neville, Monique Anderson, Andrew J Brent, Nicola Jones, Lucas Martins Ferreira, Thomas Christott, Brian Marsden, Sarah Hoodally, Richard Connell, Derrick W Crook, Dave Stuart, Gavin Smeaton, Oxford University Hospitals Staff Testing Group, Timothy EA Peto, Bruno Holthof, Anne-Marie O'Donnell, Daniel Ebner, Christopher P Conlon, Katie Jeffery, Timothy P Walker

doi: <https://doi.org/10.1101/2020.06.24.20135038>

<https://www.medrxiv.org/content/10.1101/2020.06.24.20135038v1>



Birmingham HCWs

Respiratory Infection

ORIGINAL RESEARCH

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study

Adrian Shie¹, Joel D Allen¹, Daniel Ebar¹, Golaleh Mc¹, Danai Papa¹, Eloise M W¹, Agnieszka E Zielinska⁴, Max Crispin⁵, David C Wraith^{4,10}, Adam F Cunningham⁸, Mark T Drayson^{1,10}, Alex G Richter^{1,2}, Sian Jossi³, Erin Aldera⁴, Josworth², Lyndsey A Dunbar¹, Anna Gray², I Michael Kidd⁶, Jojo⁷, Joanna O'Neill², on⁸, Megan Richter⁸, habe^{3,9}, Celina Whalley⁸, Andrew D Beggs⁸


Birmingham 545 HCWs

ABSTRACT
Objective To determine the rates of asymptomatic viral carriage and seroprevalence of SARS-CoV-2 antibodies in healthcare workers.
Design A cross-sectional study of asymptomatic healthcare workers undertaken on 24/25 April 2020.
Setting University Hospitals Birmingham NHS

Key messages
What is the key question?
<https://thorax.bmj.com/content/thoraxjnl/ear/2020/08/28/thoraxjnl-2020-215414.full.pdf>

For numbered affiliations see end of article.

Correspondence to Professor Alex G Richter, Clinical Immunology Service, University of Birmingham College of Medicine and Dental Sciences, Birmingham B15 2TT, UK.



medRxiv THE PREPRINT SERVER FOR HEALTH SCIENCES

Community prevalence of SARS-CoV-2 in England: Results from the ONS Coronavirus Infection Survey Pilot

ONS – PCR surveillance

Staying at home	1
Working outside home	2.49 (1.4-4.5)
Non-patient facing work	1
Patient facing work	4.06 (2.4-6.8)
Contact with hospital – personally	2.20 (1.1-4.2)
Contact with hospital – household member	1.99 (0.9-4.1)

61% of +ves asymptomatic

<https://www.medrxiv.org/content/10.1101/2020.07.06.20147348v1>

Infection rates


HCW vs community

<u>PCR</u>		
ONS		4x
<u>Serology</u>		
UCL	45 vs 15%	3x
Birmingham	24 vs 6%	4x
Oxford	11% vs 6%	2x

Anaesthesia and ICM under-represented

- HCW infection
- Deaths


Three epidemics





Waning antibodies

- wane after 3-4 months
- reinfection possible
- survived is not untouchable

Simon Lennane	GP, Ross on Wye
Emira Kusmurovic	Health Service Research Centre Fellow, RCoA
Lesa Kearney	Teaching Fellow, Kings Hospital
Ella Woodman	Physiology Undergraduate








NHS workforce - % BAME (2018)


All	21%
Nurses	20%
HSWs	17%
Doctors	44%
Born outside UK	18%

<https://digital.nhs.uk/data-and-information/publications/statistical/nhs-workforce-statistics/september-2018>


BAME
% Deaths vs % NHS workforce



May - 31 doctors



May - 31 doctors



Doctor deaths

Anaesthesia 2020, 75, 989-992 doi:10.1111/anae.15116

Editorial
Deaths in healthcare workers due to COVID-19: the need for robust data and analysis

E. Kurumovic,^{1,2} S. Lennane³ and T.M. Cook^{1,4}

¹ National Audit Fellow, Health Services Research Centre, National Institute of Academic Anaesthesia, Royal College of Anaesthetists, London, UK
² Specialty Registrar, A Consultant, Department of Anaesthesia and Intensive Care Medicine, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
³ General Practitioner, Rose-on-Wye, Herefordshire, UK
⁴ Honorary Professor of Anaesthesia, University of Bristol, UK

Correspondence to: T. Cook
Email: tcook078@gmail.com
Accepted: 7 May 2020
Keywords: COVID-19; healthcare workers; infection; mortality
Twitter: @tkurumovic, @stlennane, @tcook078

The novel coronavirus Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has rapidly spread across the world from its origin in Wuhan, China in late 2019. The resultant coronavirus disease 2019 (COVID-19) has placed an enormous burden on healthcare systems due to the high transmission rates, prevalence of severe disease and mortality [1]. The risk of viral transmission to healthcare workers has been a concern since the start of the outbreak and the first serious concern arose about the illness in the

We identified 119 deaths from publicly visible reports; 106 were confirmed. Based on these media reports and one social media report and analysed. In the vast majority of cases we were able to establish that the individuals had been working before death and the degree to which their job was patient-facing. However, it was not possible to determine whether healthcare workers became infected at work or elsewhere.

One element of focus was whether, as a last function

Anaesthetist/Intensivist safety

1. Better PPE
2. Better behaviours
3. AGPs are not aerosol generating?
4. Infection risk burnt out before ICU?

Is the population safe?	No (age)
Are hospitals safe	No (keep the virus out)
Are anaesthetist and intensivists safe?	Yes (With present protection)n

Thank you
timcook007@gmail.com
@doctimcook
